Journal profile · Medicine-Internal Medicine
Therapeutic Advances in Rare Disease
ISSN 2633-0040 · SAGE Publishing · United Kingdom
Therapeutic Advances in Rare Disease: diamond open access (no APC); no APC; median 199 days to acceptance (45 articles, last 24 months); acceptance rate 55% (journal website); 24 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Therapeutic Advances in Rare Disease is published by SAGE Publishing. By OpenAlex counts of its recent articles, its largest topics are Genomics and Rare Diseases, Metabolism and Genetic Disorders and Lysosomal Storage Disorders Research, together about 37.5% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Therapeutic Advances in Rare Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on the diagnosis and medical treatment of rare diseases and orphan drugs. The journal has a strong research and clinical focus and is aimed at clinicians, researchers in both academia and healthcare industries, as well as manufacturers through to policy-makers, providing an online forum for publishing the highest quality articles in this area.The editors welcome original research articles across all areas of rare disease including:
· Clinical genetics and genomics
· Dysmorphology
· Ethical and legal perspectives
· Inherited metabolic diseases
· Lysosomal storage diseases
· Mitochondrial Diseases
· Orphan Drugs
· Rare bone diseases and skeletal dysplasias
· Rare cardiovascular diseases
· Rare coagulation diseases
· Rare endocrinological diseases
· Rare gastrointestinal diseases
· Rare immune deficiencies
· Rare infectious diseases
· Rare kidney diseases
· Rare neurological diseases
· Rare ophthalmological diseases
· Rare respiratory diseases
· Rare skin diseases
· Rare tumors
· Regulatory, reimbursement and government policyTherapeutic Advances in Rare Disease conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract. The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be follows (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses).
From the journal's Aims & Scope
Research area (LetPub): Medicine-Internal Medicine
Editor-in-chief David PearcePublisher website
Editorial board by country: none in mainland China; most named United States 12, United Kingdom 9, Italy 3, Australia 2, Netherlands 2 (39 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Genomics and Rare DiseasesBiochemistry, Genetics and Molecular Biology14.5%
- Metabolism and Genetic DisordersBiochemistry, Genetics and Molecular Biology12.1%
- Lysosomal Storage Disorders ResearchMedicine10.9%
- Glycogen Storage Diseases and MyoclonusMedicine7.3%
- Genetics and Neurodevelopmental DisordersBiochemistry, Genetics and Molecular Biology5.7%
- Epilepsy research and treatmentMedicine4.8%
- Mitochondrial Function and PathologyBiochemistry, Genetics and Molecular Biology4.8%
- Genetic Neurodegenerative DiseasesNeuroscience4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Internal Medicine | Q2 | 87/179 | — |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 3.3LetPub ·
- SJR 2026-06
- 0.5LetPub ·
- SNIP 2026-06
- 0.67LetPub ·
- h-index
- 14OpenAlex ·
- i10-index
- 20OpenAlex ·
- 2-year mean citedness
- 1.96OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 146 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 24 | 24 | 146 |
| 2025 | 24 | 24 | 265 |
| 2024 | 43 | 43 | 178 |
| 2023 | 17 | 17 | 80 |
| 2022 | 16 | 16 | 44 |
| 2021 | 16 | 16 | 11 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
199 daysMedian, submission to acceptance · P25–P75 162 days – 247 days
- Acceptance to online
- median 35 days (45 articles)
- Submission to online
- median 239 days
- Sample
- 45 articles with submission and acceptance dates (0 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 15 weeksLetPub ·
- Acceptance rate (publisher)
- 55%Publisher website ·
- Submission to first decision
- 11 daysPublisher website ·
- Acceptance to publication
- 29 daysPublisher website ·
- Submission to publication (journal-reported)
- about 15 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY, CC BY-NC | |
| OpenAlex | USD 0 | — | — | |
| LetPub | No APC | No | — | |
| Publisher website | USD 2,250 / USD 5,500 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted9
- original articleView our Special Collections currently accepting submissions: /collection-index/trd Please visit the Sage Journal Author Gateway for guidance on producing visua…Length not stated
- original articlesOriginal Articles.The Editors will consider clinical interventional and observational studies with clearly stated aims, well-reported methodology (including mai…Length not stated
- original research articleView our Special Collections currently accepting submissions: /collection-index/trd Please visit the Sage Journal Author Gateway for guidance on producing visua…Length not stated
- perspectiveView our Special Collections currently accepting submissions: /collection-index/trd Please visit the Sage Journal Author Gateway for guidance on producing visua…Length not stated
- reviewView our Special Collections currently accepting submissions: /collection-index/trd Please visit the Sage Journal Author Gateway for guidance on producing visua…Length not stated
- review articleView our Special Collections currently accepting submissions: /collection-index/trd Please visit the Sage Journal Author Gateway for guidance on producing visua…Length not stated
- review articlesReview Articles. These manuscripts are usually commissioned by the Editors but unsolicited reviews will be considered.Length not stated
- scoping reviewsScoping Reviews– These reviews assess the scope of available literature on a topic through comprehensive synthesis.Length not stated
- systematic reviewView our Special Collections currently accepting submissions: /collection-index/trd Please visit the Sage Journal Author Gateway for guidance on producing visua…Length not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, Publication ethics, Open access, Peer review, Plagiarism, Preprints, Trial registration / reporting guidelines
- Authorship Author contributions
As part of our commitment to ensuring an ethical, transparent and fair peer review and publication process, this journal has adopted CRediT (Contributor Roles Taxonomy). CRediT is a high-level taxonomy, including 14 roles, which is used to describe each author’s individual contributions to the work. You will be asked to list the contribution of each author as part of the submission process. Please…
Source ↗Publisher website ·- Data availability Data availability
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…
Source ↗Publisher website ·- Publication ethics Ethical considerations
COPE member Model summary
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…
Source ↗Publisher website ·- Open access Publishing fees and open access
Therapeutic Advances in Rare Disease is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. The article processing charge (APC) is $2,250 USD. More details on APCs for specific article types can be found in the Article Type section below. The arti…
Source ↗Publisher website ·- Peer review Peer review policy
Single anonymized peer review Model summary
The following summary describes the peer review process for this journal: Identity transparency: Single-anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…
Source ↗Publisher website ·- Plagiarism Plagiarism
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
Source ↗Publisher website ·- Preprints Preprints
Preprints accepted Model summary
The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical trial registration
The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- SAGE Publishing
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2633-0040
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Therapeutic Advances in Rare Disease
How long does peer review take at Therapeutic Advances in Rare Disease?
Based on the dates recorded on 45 articles published between November 2024 and November 2026 (the last 24 months), the median time from submission to acceptance is 199 days (interquartile range 162–247 days); authors report an average review time of about 15 weeks; the journal's website gives an acceptance rate of 55%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Therapeutic Advances in Rare Disease based?
Of the 39 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (12), United Kingdom (9) and Italy (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Therapeutic Advances in Rare Disease?
According to LetPub and DOAJ records, Therapeutic Advances in Rare Disease is indexed in Scopus and DOAJ.
Is Therapeutic Advances in Rare Disease open access, and what is the APC?
Therapeutic Advances in Rare Disease is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .